Six Peptides Win Compounding Access as HHS Overrides FDA Staff

Health and Human Services Secretary Robert F. Kennedy Jr. has authorized broader compounding access to six restricted peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax — over the opposition of FDA scientific staff. The move sidesteps the agency's approval process entirely. None of the six peptides is FDA approved, and none has been added to the 503A Bulks List.

The July Pharmacy Compounding Advisory Committee (PCAC) vote in favor of loosening restrictions was advisory only. The new "interim enforcement discretion policy" goes further: compounding pharmacies may mix the six peptides, and HHS will not take enforcement action against them, provided every condition is met. The industry has entered "genuinely new territory," says Dustin Robinson, a lawyer and founding partner of LumaLex Law, a firm advising businesses in emerging health sectors.

What are the conditions for pharmacies?

Robinson explains that pharmacies are protected only if they satisfy every rule, including:

• Raw ingredients must come from FDA-registered manufacturers following good manufacturing practices.
• Each ingredient needs a certificate of analysis (COA) covering identity, purity, endotoxins and the absence of contaminants such as heavy metals.
• Each product can contain only one peptide.
• Each peptide is limited to specific forms — intranasal use for Semax, for example.
• The products require a prescription from a licensed physician; none can be purchased over the counter.

The HHS document singles out Kennedy, a vocal peptide advocate who is not a medical professional. "The Secretary of HHS has determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients," it reads. Based on "available evidence" and the PCAC recommendations, "the Secretary has determined that the policy advances patient choice and freedom while appropriately protecting patient safety."

Does the FDA agree with RFK Jr.'s decision?

No. The Associated Press reports that FDA staff helped create the safety guardrails, but that "Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development." None of the six peptides has completed the FDA approval process. The Associated Press also recently linked Australian actor Richard Norton's 2025 death to excess use of a prescription peptide — not one of the six.

David J. Holt, attorney and owner of Holt Law, a health-care business law firm in Minnesota and California, says the policy is tempting to read as an FDA bypass but is "actually a highly specific safety valve" meant to "immediately rescue patients from a dangerous black market" — the "for research purposes only" loophole that lets consumers buy peptides without medical oversight. The policy covers state-licensed pharmacies, federal facilities and physicians compounding for patients with prescriptions, according to Jay Campbell, co-founder of the American Peptide Association. Pharmacies must report serious adverse events to the FDA and label products as compounded drugs not for resale.

"Those are exactly the safeguards consumers have needed for years," says Holt. He adds that the policy is "a smart move to bring some manufacturing and related commerce in the peptide space back into the United States, as massive importing is currently occurring."

What precedent does the policy set?

Campbell sees two standards. The first is political: "HHS has shown it will act on peptides even when the FDA's career staff disagree, and that precedent will shape what happens to the next group [of peptides to be reviewed]." The second is quality, since the policy "spells out exactly what testing a peptide should pass before it reaches a human being." Required adverse-event reporting should also generate more "real-world evidence," he says. "This should become the floor for every peptide sold in this country, not just the six in this policy."

Don't expect overnight change: pharmacies need to build compliant supply chains first, Robinson notes. Holt calls the intervention rare, citing a "perfect storm: massive consumer demand, an existing PCAC advisory vote in favor of these peptides, a federal administration that appears pro-patient choice related to peptides, and finally a bureaucratic FDA rulemaking process that takes years to finalize." His warning: "this is not a green light for medical and wellness clinics to start compounding every peptide that pops up in their social media feed." The same PCAC panel is expected to weigh the next batch of peptides in February, and Robinson notes a future administration could reverse the policy "overnight."

What about scientific validation?

"Access should never be confused with scientific or clinical validation," says Ava Shamban, MD, a board-certified California dermatologist who has served as an investigator in FDA trials. The policy "does not necessarily establish a new standard for FDA approval," she says, which "still requires rigorous evaluation of safety, efficacy, dosing, and manufacturing quality and further testing."

Steve Kates, PhD, vice president of regulatory affairs at Dicerna Pharmaceuticals, points to the benchmark: Ozempic was tested on thousands of people, creating a "massive amount" of safety data before approval. The same data does not exist for these six peptides. Efficacy typically requires "two well-controlled clinical trials," and existing peptide trials are not "statistically significant," he says. "Purity, sterility, consistency, and immune reactions are legitimate concerns, particularly with injectable compounds," Dr. Shamban adds. "The red flag is the precedent this could create if access substitutes for evidence."

Will prices rise?

Probably. Robinson says the rules "cut out most of the overseas supply chain," so capacity may be "tight" at first, and access will run through telehealth prescriptions. Campbell expects prices to "climb substantially" as demand spikes and testing costs rise, meaning gray-market buyers will likely keep buying there. Popular multi-peptide "stacks" are not covered by the declaration.

Amanda Kahn, MD, a board-certified internist in New York City, calls the policy a "significant development" for longevity, regenerative and preventative medicine, closing "a growing disconnect between patient demand for peptide therapies and the regulatory framework governing access." But she would never encourage patients to "experiment with injectable peptides on their own." Koehl Robinson, CEO of telehealth company CeliaRx — whose 503A pharmacy opens in 2027 — says regulators are now evaluating "peptides compound by compound… instead of treating the whole category as one risk," adding: "we won't move faster than the quality allows."

Dustin Robinson's closing frame: HHS "made a policy call, not a scientific finding that they're safe or that they work." With the PCAC panel due to review the next peptide group in February, the enforcement-discretion route — not FDA approval — now looks like the operating template.